menu
    • menu
    [{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen-beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Reparixin","moa":"IL-8","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ladarixin","moa":"IL-8A receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reparixin","moa":"IL-8","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen-beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Dompe Farmaceutici

    Menu

    Dompe Farmaceutici

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dompe Farmaceutici

                            Italy arrow
                            Interphex
                            Not Confirmed

                            Dompe Farmaceutici

                            Italy arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Raloxifene Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Two Clinical Studies to Treat Mild-to-Moderate COVID-19 at Home Reveal Value of Exscalate, Dompé's AI Platfor...

                            Details : Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 26, 2022

                            Lead Product(s) : Raloxifene Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dompe Farmaceutici

                            Italy arrow
                            Interphex
                            Not Confirmed

                            Dompe Farmaceutici

                            Italy arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Reparixin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dompé Announces Results of Phase 2 Study Evaluating the Efficacy and Safety of Reparixin in Patients with Sev...

                            Details : In hospitalized patients with COVID-19 Pneumonia, the rates of clinical events among those treated with Reparixin (n=36) were statistically significantly lower than standard of care (n=19).

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 13, 2022

                            Lead Product(s) : Reparixin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dompe Farmaceutici

                            Italy arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed

                            Dompe Farmaceutici

                            Italy arrow
                            Peptide-Based Therapeutics Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Raloxifene Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EXSCALATE4COV: Italian Medicines Agency (AIFA) authorizes Raloxifene Clinical Trial for Paucisymptomatic Covid...

                            Details : A patent on the use of raloxifene for the treatment of people affected by COVID-19 was filed by Dompé farmaceutici, Fraunhofer Institute and Leuven University to promote universal access to related therapies that may be developed, in line with Exscalate...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 27, 2020

                            Lead Product(s) : Raloxifene Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Dompe Farmaceutici

                            Italy arrow
                            Interphex
                            Not Confirmed

                            Dompe Farmaceutici

                            Italy arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ladarixin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dompé Presents Phase II Clinical Trial Results for Ladarixin in New-Onset Type 1 Diabetes

                            Details : Results from Phase 2 trial demonstrate that ladarixin, a novel small molecule that inhibits the biological activity of IL-8, has potential activity in the preservation of β-cell function in new-onset type 1 diabetes (T1D).

                            Product Name : MEX0114

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 15, 2020

                            Lead Product(s) : Ladarixin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Dompe Farmaceutici

                            Italy arrow
                            Interphex
                            Not Confirmed

                            Dompe Farmaceutici

                            Italy arrow
                            Interphex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Reparixin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ANVISA Authorizes Dompé's REPAVID-19, a Phase 2 Clinical Trial for Treatment of Severe Patients

                            Details : The REPAVID-19 clinical trial will evaluate efficacy and safety of Dompé’s Reparixin in hospitalized adult patients with severe COVID-19 pneumonia.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 09, 2020

                            Lead Product(s) : Reparixin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth